SAREPTA THERAPEUTICS, INC. (SRPT)

Every figure this model derived for SRPT, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 29,161,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 788,489,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 2,223,824,000 AssetsCurrent 2026-06-30
current liabilities 502,908,000 LiabilitiesCurrent 2026-06-30
equity 1,527,798,000 StockholdersEquity 2026-06-30
interest expense 75,696,000 InterestExpense 2026-06-30
ocf 111,008,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 1,974,344,000 Revenues 2026-06-30
sbc 98,814,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up SRPT on one particular measure came for.

RatioValue
cash operating margin0.01
current ratio5.66
current ratio reported4.42
deferred revenue growth-72.15
dilution pct-7.19
fcf margin4.15
growth cv0.36
interest cover-1.89
operating margin-7.26
owner earnings margin-0.86
revenue growth-20.44
revenue growth per share-14.27
roic-7.13
rule of 40-27.69
sbc pct revenue5.0

What to be careful about

What this model itself distrusts about SRPT's figures. Written by the derivation as it ran, not added afterwards.